Ind-Swift Laboratories has launched generic formulations of atorvastatin in the UK in collaboration with Wockhardt UK on the first day of its patent expiry. Atorvastatin, is the one of the world’s best selling drug with world market size of $ 16 billion. The drug went off patent in Europe on May 6, 2012 and taking this opportunity Ind Swift and its EU marketing partner Wockhardt UK launched the generic version of the molecule in UK on the first day after the patent expiry. The product was launched in all its strengths i.e. 10 mg, 20 mg, 40 mg and 80 mg.
The API required for the product was supplied from the US FDA and MHRA approved plant of Ind – Swift Laboratories and the formulations was manufactured and supplied from the 100 per cent export oriented facility of Ind-Swift located at Jawaharpur near Derabassi Punjab.
The first day launch of atorvastatin in collaboration with its marketing partner Wockhardt UK is a significant achievement for Ind Swift. Speaking on the occasion Sirjiwan Singh, Managing Director, Wockhardt UK said, “Wockhardt UK is one of the major suppliers of healthcare products to the retail pharmacy and hospitals in the UK and the launch of generic version of atorvastatin in collaboration with Ind Swift is an important milestone for us.”
NR Munjal, Vice Chairman, Ind-Swift added, “With increase in demand for cost effective drugs for cardiovascular diseases, this generic launch is an excellent example of collaborative efforts of the two companies in leveraging on mutual strengths and competencies. We are targeting to capture a significant market share of this product in the UK within the first year of launch.” He added that more such products will be launched in the European market in near future.
EP Bureau – Mumbai
